logo-loader

ChemioCare 'exceeding expectations' with pace of developing its technology

Published: 13:52 18 Oct 2018 EDT

ChemioCare USA Inc CEO Pedro Lichtinger sits down with Proactive Investors' Christine Corrado at the BIO Investor Forum in San Francisco.

Lichtinger says the New York based company, which is aiming to transform patient outcomes in cancer supportive care through its platform of transdermal patches using proprietary technology, says the company has completed its first proof of concept in animals for its transdermal patch.

By the summer of 2019, Lichtinger says the company should be ready to launch its Phase III clinical program.

Ramp Metals Launches Drilling Program in Pursuit of High-Grade Nickel in...

Ramp Metals CEO Jordan Black joined Steve Darling from Proactive to introduce the company to the public domain and share exciting developments in the mining industry. With a background as a geotechnical engineer and experience in venture capital, including a notable role in taking GoldSpot...

1 hour, 27 minutes ago